Skip to main content
Article thumbnail
Location of Repository

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

By Michele Maio, Hugues JM Nicolay, Paolo Ascierto, Filippo Belardelli, Roberto Camerini, Mario P Colombo, Paola Queirolo, Ruggero Ridolfi, Vincenzo Russo, Lucia Anzalone, Ester Fonsatti and Giorgio Parmiani


As for a consolidated tradition, the 5th annual meeting of the Italian Network for Cancer Biotherapy took place in the Certosa of Pontignano, a Tuscan monastery, on September 20–22, 2007. The congress gathered more than 40 Italian leading groups representing academia, biotechnology and pharmaceutical industry. Aim of the meeting was to share new advances in cancer bio-immunotherapy and to promote their swift translation from pre-clinical research to clinical applications. Several topics were covered including: a) molecular and cellular mechanisms of tumor escape; b) therapeutic antibodies and recombinant constructs; c) clinical trials up-date and new programs; d) National Cooperative Networks and their potential interactions; e) old and new times in cancer immunology, an "amarcord". Here, we report the main issues discussed during the meeting

Topics: Commentary
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2006). A: Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-{alpha}. Clin Cancer Res
    2. (2006). Acquati M: Targeted therapies in melanoma. Cancer Treatment Reviews
    3. (2007). Amadori A: Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Res
    4. (2007). Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer
    5. (2002). Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications.
    6. (2007). D: GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy
    7. (2004). Disis M: Conflicts of interest in translational research.
    8. (2003). Eggermont A: Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms.
    9. (2007). Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    10. (2004). F: Lost in Translation: Obstacles to Translational Medicine.
    11. (2006). Finocchiaro G: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res
    12. (2006). Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems.
    13. (2007). Italian Trials in Medical Oncology
    14. (2008). LK: Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
    15. (2004). Materializing research promises: opportunities, priorities and conflicts in translational medicine.
    16. (2002). Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends in Immunology
    17. Piconese S: Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
    18. (2007). Proietti E: Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration. Clin Cancer Res
    19. (2006). Regulation of the T cell response. Clin Exp Allergy
    20. (2005). Rescigno M: Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. Cancer Res
    21. (2007). Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.
    22. (2006). Riccobon A: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients.
    23. (2006). Rivoltini L: Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-{beta}-Mediated Suppressive Activity on T Lymphocytes. Cancer Res
    24. (2007). Rivoltini L: Vaccination therapy in prostate cancer. Cancer Immunol Immunother
    25. (2006). S: Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness.
    26. (2005). SA: Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With AntiCytotoxic T-Lymphocyte Antigen-4. J Clin Oncol
    27. (2007). Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
    28. (2004). Translation research: from accurate diagnosis to appropriate treatment.
    29. (2003). Vaccination of patients with solid tumours. Ann Oncol
    30. (2006). Why is public science education important?

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.